QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Patent law shift tilts enforcement toward inventors—and away from generic competition

H.R. 1574 — RESTORE Patent Rights Act of 2025 · Filed by Nathaniel Moran (R-TX) · 5 cosponsors · Introduced Feb 25, 2025 · Referred to committee

75%
Transparency
Typical bill: 82%
15/100
Hidden-provision risk
Typical bill: 15/100
Patent Enforcement Strengthening

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This bill amends patent law to create a legal presumption that courts should grant permanent injunctions (court orders stopping infringement) when a patent owner wins an infringement case, unless the defendant can rebut that presumption with equitable defenses. The bill aims to restore what Congress characterizes as the historical practice of presumptive injunctions, which it argues has been eroded by recent court decisions, and to protect patent owners—especially individual inventors, universities, startups, and small businesses—from continued infringement by large companies.

Why we flagged it

The bill's operative mechanism is a single, clearly stated change to patent remedies law: it restores a rebuttable presumption of injunctive relief upon infringement judgment. This is a straightforward doctrinal shift in patent litigation procedure, not a hidden rider or concealed benefit.

What the text implies

  • Presumptive injunctions may increase settlement leverage for patent holders, potentially leading to higher licensing fees and royalties that flow through to consumer prices for patented products and services.
  • Small patent holders and universities may gain enforcement power, but the bill does not distinguish between legitimate patents and low-quality or overly broad patents—all infringement judgments trigger the presumption equally.

The full analysis lists 4 implications of this text.

Who stands to gain

patent holders (individual inventors, universities, startups, small/medium enterprises); patent licensing firms and patent aggregators; pharmaceutical companies holding patent portfolios

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record